Intrigue Grows Around Rigel Pharmaceuticals’ (RIGL) Drug


Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) stock surged 1.15% (or +$0.03) to $2.64 and 1.95M of its shares changed hands on Monday, representing a large increase in activity versus its average volume (3m) of 662,343

Rigel Pharma said after the closing bell that it will report data of the first of two FIT data of the first of two FIT late-stage studies evaluating its oral spleen tyrosine kinase inhibitor fostamatinib in patients with immune thrombocytopenia on Tuesday, August 30 at 4 AM Pacific/7 AM Eastern Time.

Shares of the clinical-stage biotechnology company climbed more than 15% in the extended session, following the announcement

Rigel Pharmaceuticals, which engages in the discovery and development of targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology, has 94.59M Shares Outstanding, Market Capitalization (intraday) of $249.72M and RIGL stock 52-week range is from $1.88 to $3.68 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at